Monday, February 15, 2021

Arkansas Case re Breadth of Intention of 1115A Demonstrations (Medicaid)

 States of Medicaid Work Requirement Policy Reversals

Reporting this week suggests that President Biden will notify the states that have been approved to implement conditions for Medicaid eligibility tied to employment or similar requirements that basis for this flexibility is no longer in effect. To further implement the policy change, CMS is expected to withdraw 2018 guidance that encouraged states to experiment with work requirements to advance a purpose not expressed in the Medicaid statute: to improve beneficiaries’ health and well-being. The actions will not have a practical impact to state programs as no state currently operates such work requirements, due to a combination of court injunctions setting aside the programs or state voluntary actions stemming from litigation threats as well as the COVID-19 public health emergency (preventing terminations). 


The actions may affect the course of the pending U.S. Supreme Court case regarding the approvals of the Arkansas and New Hampshire work requirement demonstrations if the Court determines the case is now moot. 


If the case moves forward, the Court may ultimately decide a larger question underpinning this policy as to whether CMS has discretion to create purposes not expressed in the statute and in turn, approve demonstration projects that advance such agency-created purposes


AND

https://www.washingtonpost.com/health/biden-ends-medicaid-work-requirements/2021/02/11/74b51d78-6cc3-11eb-9f80-3d7646ce1bc0_story.html?utm_campaign=wp_the_health_202&utm_medium=email&utm_source=newsletter&wpisrc=nl_health202


Biden administration to move Friday to rescind Medicaid work requirements

In its planned announcement, the Biden administration said the requirements were especially unwise during the coronavirus pandemic, which has sickened millions of Americans and forced many out of work. The agency overseeing Medicaid “has serious concerns that now is not the appropriate time to test policies that risk a substantial loss of health care coverage or benefits,” according to the draft plan.

According to the 15-page document, the Trump administration approved work programs in 13 states, and 10 others were still seeking approval. A few withdrew when GOP governors were replaced by Democrats. Arkansas was the only state that actually implemented its requirements, and 18,000 poor residents there were removed from Medicaid rolls over several months before the program was blocked by a judge on the U.S. District Court for the District of Columbia.

Accompanying the steps to reverse the Trump policy, HHS also plans to release an analysis Friday assessing how the Trump policy limited low-income Americans’ access to health coverage, according to the two individuals familiar with the plans.

The analysis was overseen by Ben Sommers, a longtime Harvard researcher who joined HHS last month as a deputy assistant secretary for strategy and planning and had previously written about the drawbacks of Medicaid work requirements, the officials said. “[W]e found no evidence that the policy succeeded in its stated goal of promoting work and instead found substantial evidence of harm to health care coverage and access,” Sommers and colleagues wrote in a September 2020 analysis in the journal Health Affairs.

Sommers did not respond Thursday night to a request for comment

###

The MFN Most Favored Nation legal cases also deal with breadth of intention of 1115A.


###


Friday, February 12, 2021

Some LInks about Gapfill (2/2021)

See main blog to which this article provides background and footnotes - here.






CMS REGULATION
x

CMS INFO
Policy up to 2021 and CMS correspondence this year suggests all MACs will price all codes officially put into the Gapfill process.

CMS website says all MACs will price all codes (2/12/2021).

For any new test code that will be gapfilled, we request our MACs to develop MAC-specific gapfilled amounts for each test code and report the amount to CMS by April 1 of the following year. 

CMS transmittal for 2020 was here, CR11598:  https://www.cms.gov/files/document/r4498cp.pdf

CMS transmittal for 2021 is here, CR12080:   https://www.cms.gov/files/document/r10575CP.pdf 

MAC INFO
Both NGS MACs and MolDx stated to consultants by email circa 2/2021 that only codes for lab tests in their jurisdictions would be accepted and reviewed for gapfill 2021. (See however points 1,2 above, which is different and suggests CMS needs info for all codes).

MOLDX gapfill worksheet, Excel, webpage, here:

NOVITAS Gapfill web page here (leads to tabular web portal for data entry):

FCSO Gapfill web page here (leads to tabular web portal for data entry):

NO OTHER INFORMATION
  • NGS MAC had no information on GAPFILL rules or processes or how to submit.
  • CGS, WPS, NORIDIAN MACs had no information, separate from MolDx home website, using GAPFILL as a keyword search.   
  • Palmetto GBA MAC had no hits for “Gapfill” although there is a webpage, as cited on the MOLDX separate homepage.


 

Thursday, February 4, 2021

What's happening to Prior Auth rule?

On January 12, CMS released the MCIT rule, and it was published in the Federal Register on January 14.

On January 15, CMS released the final "prior auth" rule, in inspection-copy form, with a press release.  I believe it has never appeared in the Federal Register, and I learned on February 4 the rule's PDF and the rule's Press Release were deleted from the CMS website.

This is at variance with a January 26 article at Becker's Hospital Review.  That article said that three rules were being withdrawn:

  • Medicare Part A enrollment;
  • Altered dialysis rules;
  • Oversight of accreditation organizations.
But the Becker's article said that three rules would go forward:
  • A rule for prior authorizations,
  • A rule for breakthrough technologies,
  • An update of 'reasonable and necessary' regulations (the 2nd and 3rd points are in one published rule, Fed Reg, Jan 14).
https://www.beckershospitalreview.com/finance/cms-withdraws-3-proposed-health-rules.html

##

A drug pricing rule (MFN) is officially delayed for a year; it is tied up in court anyway.
https://khn.org/morning-breakout/biden-administration-delays-trumps-drug-pricing-rebate-rule-for-a-year/


SurveyMonkey Website Captured 2/4/2021

 https://www.surveymonkey.com/r/MolecularDiagnosticPathology


* 1. Procedure Code


2. Clinical Vignette

Question Title

3. How was this service billed previously?

Question Title

4. Please classify the test billed under the applicable code as one of the following (check one):

Question Title

5. List the resources required to perform the test and the cost:

Question Title

6. Total charges for the test and routine discounts to the charges:

Question Title

7. If applicable, charges, payment amounts, and resources required for other test(s) that may be comparable or otherwise relevant:

Question Title

8. Please provide your direct/indirect costs associated with this test (please be specific):

Question Title

9. Additional comments or information:

Question Title

10. Please click here if you would like to attach additional supporting documentation:

 
 

Question Title

* 11. Address

FCSO Gapfill Website Captured 2/4/2021

 https://medicare.fcso.com/Clinical_lab/0456242.asp


2021 Gap-fill survey

First Coast Service Options, Inc. (First Coast), the Medicare administrative contractor (MAC) for Jurisdiction N (JN) is in receipt of the new laboratory test codes identified by the Centers for Medicare & Medicaid Services (CMS) to be gap-fill priced for 2021. The Protecting Access to Medicare Act (PAMA) regulations instruct the MACs to establish local payment amounts for the new laboratory test codes using the following sources of information, if available:
1. Charges for the test and routine discounts to charges
1. Resources required to perform the test
2. Payment amounts determined by other payors
3. Charges, payment amounts, and resources required for other tests that may be comparable or otherwise relevant
First Coast seeks your input on establishing pricing under the Medicare program for new laboratory test codes 86328, 86769, 87635, 0101U, 0102U, 0103U, 0129U, 0139U, 0140U, 0141U, 0142U, 0143U, 0144U, 0151U, 0152U, 0153U, 0156U, 0157U, 0158U, 0159U, 0160U, 0161U, 0162U, 0163U, 0164U, 0165U, 0171U, 0173U, 0174U, 0175U, 0178U, 0179U, 0180U, 0206U, 0207U, 0208U, 0209U, 0212U, 0213U, 0214U, 0215U, 0216U, 0217U, 0219U, 0220U, 0221U, 0222U, 0015M, 0016M, U0001, U0002, U0003, and U0004. To that end, First Coast kindly requests that you complete our https://www.surveymonkey.com/r/MolecularDiagnosticPathology external link by March 8, 2021.
Please note that your answers will be kept to the greatest degree of confidentiality and will not be disclosed, except as may be necessary to share with others under confidentiality agreements with CMS for the sole purpose of establishing Medicare clinical laboratory fee schedule gap filling pricing.
Your responses will be reviewed and evaluated by First Coast and if proper, set forth in its recommendations to CMS of the appropriate fees for these tests. If no response is received, the fee will be determined by evaluating the charges, payment amounts, and resources required for other tests that may be comparable or otherwise relevant.
Note: The presence of an established local payment amount does not imply coverage.

Novitas Gapfill Info Website (Captured 2/4/2021)

 https://www.novitas-solutions.com/webcenter/portal/MedicareJH/pagebyid?contentId=00246106


2021 Gap-fill Survey

Novitas Solutions, Inc. (Novitas), the Medicare Administrative Contractor (MAC) for Jurisdictions H and L (JH and JL) is in receipt of the new laboratory test codes identified by the Centers for Medicare & Medicaid Services (CMS) to be gap-fill priced for 2021. The Protecting Access to Medicare Act (PAMA) regulations instruct the MACs to establish local payment amounts for the new laboratory test codes using the following sources of information, if available:

1. Charges for the test and routine discounts to charges
2. Resources required to perform the test
3. Payment amounts determined by other payors
4. Charges, payment amounts, and resources required for other tests that may be comparable or otherwise relevant

Novitas seeks your input on establishing pricing under the Medicare program for new laboratory test codes 86328, 86769, 87635, 0101U, 0102U, 0103U, 0129U, 0139U, 0140U, 0141U, 0142U, 0143U, 0144U, 0151U, 0152U, 0153U, 0156U, 0157U, 0158U, 0159U, 0160U, 0161U, 0162U, 0163U, 0164U, 0165U, 0171U, 0173U, 0174U, 0175U, 0178U, 0179U, 0180U, 0206U, 0207U, 0208U, 0209U, 0212U, 0213U, 0214U, 0215U, 0216U, 0217U, 0219U, 0220U, 0221U, 0222U, 0015M, 0016M, U0001, U0002, U0003, and U0004. To that end, Novitas kindly requests that you complete our molecular diagnostic pathology survey by March 8, 2021.

Please note that your answers will be kept to the greatest degree of confidentiality and will not be disclosed, except as may be necessary to share with others under confidentiality agreements with CMS for the sole purpose of establishing Medicare clinical laboratory fee schedule gap filling pricing.

Your responses will be reviewed and evaluated by Novitas and if proper, set forth in its recommendations to CMS of the appropriate fees for these tests. If no response is received, the fee will be determined by evaluating the charges, payment amounts, and resources required for other tests that may be comparable or otherwise relevant.

Note: The presence of an established local payment amount does not imply coverage.

Monday, February 1, 2021

Copy of AMA CPT process calendar

 https://www.ama-assn.org/about/cpt-editorial-panel/cpt-editorial-panel-meeting-process-calendar


Find a calendar listing the upcoming meetings of the Current Procedural Terminology (CPT®) Editorial Panel.

New CPT codes have been created that streamline novel coronavirus testing, vaccines and immunization administration currently available on the United States market.


The submission due date for code applications is 12 weeks prior to the Panel meeting. Review the code application deadlines.

Feb. 4-6, 2021

  • Location: Virtual
  • Submission of code application due date: Nov. 4, 2020

May 6-8, 2021

  • Location: TBD
  • Submission of code application due date: Feb. 11, 2021

Sept. 30-Oct. 2, 2021

  • Location: TBD
  • Submission of code application due date: June 30, 2021

*These deadlines refer to Pathology/Laboratory Applications only (Including Molecular Pathology, MAAA, GSP)

Feb. 4-6, 2021

  • Lab application listing posted to AMA website*: Nov. 11, 2020
  • Lab interested stakeholder request for application materials due date*: Nov. 20, 2020
  • Lab interested stakeholder written comments due date: Nov. 30, 2020

May 6-8, 2021

  • Lab application listing posted to AMA website*: TBD
  • Lab interested stakeholder request for application materials due date*: TBD
  • Lab interested stakeholder written comments due date: TBD

Sept. 30-Oct. 2, 2021

  • Lab application listing posted to AMA website*: TBD
  • Lab interested stakeholder request for application materials due date*: TBD
  • Lab interested stakeholder written comments due date: TBD

Feb. 4-6, 2021

  • Meeting agenda posted to AMA website: Dec. 8, 2020
  • Interested stakeholder request for application materials due date: Jan. 14, 2021

May 6-8, 2021

  • Meeting agenda posted to AMA website: March 12, 2021
  • Interested stakeholder request for application materials due date: April 15, 2021

Sept. 30-Oct. 2, 2021

  • Meeting agenda posted to AMA website: July 30, 2021
  • Interested stakeholder request for application materials due date: Sept. 9, 2021

The Summary of Panel Actions will be posted on or before four weeks after the close of the CPT Editorial Panel meeting.

Feb. 4-6, 2021

  • Interested stakeholder written comments due date: Jan. 21, 2021
  • Summary of Panel Actions posted: March 8, 2021

May 6-8, 2021

  • Interested stakeholder written comments due date: April 22, 2021
  • Summary of Panel Actions posted: June 7, 2021

Sept. 30-Oct. 2, 2021

  • Interested stakeholder written comments due date: Sept. 16, 2021
  • Summary of Panel Actions posted: Oct. 29, 2021

 

CPT® is a registered trademark of the American Medical Association.

Up
90